- Home
- ALXO
as 01-17-2025 4:00pm EST
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 76.5M | IPO Year: | 2020 |
| Target Price: | $11.00 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.97 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.19 - $17.83 | Next Earning Date: | 03-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of ALX Oncology Holdings Inc. (ALXO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Pinto Shelly | ALXO | Interim CFO | Jan 6 '25 | Sell | $1.80 | 2,221 | $3,997.80 | 87,902 | |
| Pinto Shelly | ALXO | Interim CFO | Dec 30 '24 | Sell | $1.58 | 1,426 | $2,253.37 | 87,902 | |
| Hemrajani Rekha | ALXO | Director | Dec 2 '24 | Buy | $1.55 | 30,000 | $46,404.00 | 33,000 |
Latest ALX Oncology Holdings Inc. News
ALXO Breaking Stock News: Dive into ALXO Ticker-Specific Updates for Smart Investing
Simply Wall St.
10 days ago
3 US Penny Stocks With Market Caps Under $100M To Watch
Zacks
11 days ago
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?
GlobeNewswire
11 days ago
ALX Oncology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
MT Newswires
a month ago
Sector Update: Health Care
MT Newswires
a month ago
Top Midday Decliners
MT Newswires
a month ago
ALX Oncology Shares Fall After Downgrade From Jefferies
Investing.com
a month ago
Alx Oncology shares down in pre-market as Jefferies downgrades stock to 'hold'
MT Newswires
a month ago
Jefferies Downgrades ALX Oncology to Hold From Buy, Cuts Price Target to $2 From $12
Compare ALXO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALXO ALX Oncology Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.